Gabapentin Capsule
Product Images NDC 82868-108

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82868-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (82868 108 30 Rev A 06 26.pdf)

Gabapentin Capsules USP 100 mg label showing product name, dosage strength, and form. The label indicates a count of 30 capsules and prescription-only status. It includes storage instructions (store at 20°-25°C) and a note to see the package insert for dosage information. The labeler is Northwind Health Company, LLC, and the NDC code 82868-108-30 is visible.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula illustrating the calculation of creatinine clearance (CLCr). It includes age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure diagram of gabapentin, showing its cyclohexane ring bonded to an amine group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Gabapentin demonstrates a decrease in mean pain score over time, while placebo remains relatively stable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line chart showing mean pain scores over a 7-week period. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. Three lines represent Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, with a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart depicting the proportion of responders (patients with ≥50% reduction in pain score) at study endpoints in controlled postherpetic neuralgia (PHN) studies. It compares placebo (PBO) and gabapentin (GBP) dosages across two studies, showing higher response rates for gabapentin doses (29%, 32%, 34%) versus placebo (12%, 14%). Statistical significance is noted with p-values <0.01 and <0.001.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A chart depicting difference percentages on the y-axis versus daily dose in mg on the x-axis, showing data points for three studies labeled a, b, and c. Study a is represented by black squares, Study b by gray squares, and Study c by white squares, with differences increasing as the daily dose increases from 600 to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.